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In many settings, including oncology, increasing the dose of treatment results in both increased efficacy
and toxicity. With the increasing availability of validated biomarkers and prediction models, there is the
potential for individualized dosing based on patient specific factors. We consider the setting where there
is an existing dataset of patients treated with heterogenous doses and including binary efficacy and toxicity
outcomes and patient factors such as clinical features and biomarkers. The goal is to analyze the data
to estimate an optimal dose for each (future) patient based on their clinical features and biomarkers. We
propose an optimal individualized dose finding rule by maximizing utility functions for individual patients
while limiting the rate of toxicity. The utility is defined as a weighted combination of efficacy and toxicity
probabilities. This approach maximizes overall efficacy at a prespecified constraint on overall toxicity.
We model the binary efficacy and toxicity outcomes using logistic regression with dose, biomarkers and
dose-biomarker interactions. To incorporate the large number of potential parameters, we use the LASSO
method. We additionally constrain the dose effect to be non-negative for both efficacy and toxicity for all
patients. Simulation studies show that the utility approach combined with any of the modeling methods can
improve efficacy without increasing toxicity relative to fixed dosing. The proposed methods are illustrated
using a dataset of patients with lung cancer treated with radiation therapy.
Key words: Constrained LASSO; Efficacy toxicity trade-off; Optimal treatment regime; Person-
alized medicine; Utility.
Supporting Information for this article is available from the author.
1 Introduction
The goal of personalized medicine is to give the right treatment to the right patient at the right dose using
all we know about the patient. Available knowledge about individual patients is increasingly including
biomarkers which allow personalizing treatment decisions. One approach to personalized medicine is to
identify the right patient for a given treatment. For example, in the setting of a single binary outcome
and two potential treatments, Foster et. al (2011) proposed a “Virtual Twins” method involving predicting
response probabilities for treatment and control “twins” for each subject by random forest, and then using
regression or classification trees to identify subgroups of patients with large positive treatment effect es-
timates. A related but different approach is to identify the right treatment for a patient, often referred to
as optimal treatment regimes (OTR). A treatment regime is defined as the function that maps a patient’s
covariate vector to one of the treatment choices. One approach to identify an OTR is a 2-step method
that involves building a model for conditional expectation of the outcome given treatment as the first step,
then maximizing the mean expected reward to get the optimal treatment for each subject. In an alterna-
tive approach, rather than modeling the marginal outcome, outcome weighted learning (OWL) methods
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2 P. Li et al.: A Utility Approach to Individualized Optimal Dose Selection
maximize the reward from following a treatment regime directly, which is equal to the expected outcome
in a subset of patients who actually followed that regime, inversely weighted by the probability of being
assigned to the regime (Zhao et al., 2012). Maximizing the reward with respect to the treatment regime is
equivalent to minimizing the expectation for patients who did not follow the regime, and can be interpreted
as minimizing the weighted classification error in a classification problem (Zhang et al., 2012a). Zhang et.
al (2012b) also proposed the doubly robust augmented inverse probability weighted estimator (AIPWE) in
which an outcome model is combined with a model for the probability of a treatment which is important
when analyzing observational data. The OWL method has been extended to continuous treatment dose
settings such as optimal dose finding (Chen et al., 2016).
In many settings, it is not possible to describe a patient’s outcome using a single variable. For example,
in oncology, it is typical to describe patient outcomes in terms of toxicity and efficacy variables. Several
strategies have been proposed for identifying an optimal treatment or dose based on the trade-off between
efficacy and toxicity. Thall and Cook (2004) proposed using efficacy-toxicity trade-off contours that parti-
tion the two-dimensional outcome probability domain such that efficacy-toxicity pairs on the same contour
are equally desirable. Dose could then be selected to maximize desirability. More commonly, a utility
matrix is elicited from clinicians by assigning numerical utilities to each possible bivariate outcome. The
optimal dose is then defined as the value maximizing the posterior mean utility (Guo and Yuan, 2017). The
other approach is to set an upper limit on toxicity and choose the strategy that maximizes efficacy over the
set of doses that satisfy the toxicity limit.
Guo and Yuan (2017) proposed a Phase I/II trial design incorporating biomarkers in which the optimal
dose for an individual patient is selected to maximize utility. A joint model of ordinal toxicity and efficacy
outcomes is specified and canonical partial least squares are used to extract a small number of components
from the covariate matrix containing dose, biomarkers, and dose-by-biomarker interactions. Wang et.
al (2018) proposed two approaches to identify a personalized optimal treatment strategy that maximizes
clinical benefit under a constraint on the average risk in the situation of a with the binary treatment options
and continuous outcomes.
In this paper we propose a utility based method to estimate optimal doses for individual patients in the
setting of binary efficacy and toxicity outcomes. To allow for potentially large numbers of biomarkers
and patient factors we utilize l1-penalty via LASSO (Tibshirani, 1996). At the individual level, we find
the optimal dose by maximizing utility functions defined as the probability of efficacy minus the weighted
probability of toxicity, which is equivalent to a utility matrix (Schipper et al., 2014). The weight term
in the utility equation could be elicited from clinicians to quantify the relative undesirability of toxicity
relative to lack of efficacy. Alternatively it can be viewed as a tuning parameter selected to achieve a
desired overall (at the population level) rate of toxicity. In the vast majority of oncology treatments and
many other disease settings, both efficacy and toxicity outcomes are monotonically linked to increasing
dose. While “flat” curves are common (Postel-Vinay et al., 2009), it is uncommon for increasing dose
to lead to decreased toxicity or efficacy. We note that monotonicity may not hold for outcomes such as
progression free survival which include death as an event, since they are potentially a consequence of either
toxicity or lack of efficacy. When estimating outcomes as a function of dose only it is often not necessary
to impose this constraint. However, when including many potential dose*biomarker interactions, it is
likely that some patients will be estimated to have decreasing toxicity or efficacy with increasing dose due
to statistical noise. To prevent this and to improve efficiency we propose a method that constrains the
estimated dose-efficacy and dose-toxicity relationships to be non-decreasing for all patients. We call this
constrained LASSO, whichand it can be solved by decomposition and quadratic programming (He, 2011)
and alternating direction method of multipliers (ADMM) (Gains and Zhou, 2016). In section 3, we report
results of a simulation study and in section 4 we illustrate the proposed methods using a dataset of patients
with lung cancer treated with radiation therapy.
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2 Method
2.1 Binary Outcome Setting
We assume the available data, (xi, di, Ei, Ti), i = 1, ..., n, comprises n independent and identically dis-
tributed copies of (x, d,E, T ), where x, a p-dimensional centered vector of subject-specific features,
d ∈ [−1, 1] denotes continuous dose of treatment, E is the binary efficacy outcome, and T is the binary
toxicity outcome. A large probability of E and small probability of T is preferable.
An individualized dose rule is the map from x to the dose domain: F : Rp → [−1, 1]. Under F , a
patient with covariate x is recommended to dose d = F(x). For any treatment rule F , the population
expected efficacy and toxicity are EF (E) and EF (T ). Our goal is to estimate an individualized dose rule
that maximizes the population expected efficacy while controlling the overall expected toxicity under some
tolerance level, thatwhich is
maxF EF (E) , subject to EF (T ) ≤ τ, (1)
where τ is the pre-specified maximal tolerance level of average toxicity.
Define δE(xi, di) =P(E = 1|di, xi)−P(E = 1|di = −1, xi), δT (xi, di) =P(T = 1|di, xi)−P(T =
1|di = −1, xi). δE(xi, di) and δT (xi, di) can be interpreted as the difference in expected efficacy and
toxicity outcomes for a patient if treated at the lowest dose (di = −1) or some higher dose (di). Let Ex to
denote the population average of the function across the distribution of x. After introducing the Lagrange
multiplier,Then solving equation (1) is equivalent to
maxF Ex[δE{xi,F(xi)} − θδT {xi,F(xi)}], (2)
where θ > 0 is chosen such that Ex[δT {xi,F(xi)}] ≤ τ − Ex[P(T = 1|di = −1, xi)]. The expression
in equation (2)which is a utility function quantifying the trade-off between efficacy and toxicity. By fit-
ting separate models for E and, T using methods such as logistic regression via maximum likelihood or
constrained LASSO as described below, we can calculate the utility values for individual patients over the
range of possible dose values, and calculate the dose rule that maximizes equation (2).
ConsiderTo build the model logit{P(Y = 1)} = f(x, d, β) = β0 +Wβ between outcome Y , i.e. E or
T , and covariates including biomarkers x, dose d, and dose-biomarker interactions dx, i.e. W = (x, d, dx).
To fit the model we usewe consider the the generalized LASSO with l1-penalty onto the log-likelihood and
no penalty on β0. To enforce a non-decreasing relationship of efficacy and toxicity with dose, we add
constraints on derivatives with respect to d to be non-negative, i.e., ∂∂df(xi, d, β) ≥ 0 for all xi. We call
this method constrained LASSO (cLASSO), for which the constraint can be written as Cβ ≥ 0, where C
is a n× (2p+ 1) matrix of [0n∗p,1n∗1,xn∗p]. Then the cLASSO methodThe goal is to




subject to Cβ ≥ 0.
To solve (3) we decompose β into its positive and negative part, β = β+ − β−, as the relation
|β| = β+ + β− handles the l1 penalty term. Let W ∗ = (W,−W ), and β∗ = (β+T ,−β−T )T . By
plugging these into (3) and adding the additional non-negativity constraints on β+ and β−, the con-
strained LASSOlasso is formulated and can be solved, for example, by spg() in R, which uses the
spectral projected gradient method for large-scale optimization with simple constraints. We use 10-fold







∗)− log{1 + exp(β0 +W ∗i β∗)}] + λ14p+2Tβ∗ (4)
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subject to (C,−C)β∗ ≥ 0, β+ ≥ 0, β− ≥ 0.








exp(β0 +W ∗i β
∗)





The minimizer to (4) always satisfies β+j β
−
j = 0 for j = 1, ..., 2p+ 1, as shown in the Appendix. We use
10-fold cross-validation(CV) to choose λ to minimize the CV deviance.
For any fixed value of theta, and usingWith the above estimated models of efficacy and toxicity, we can
find the optimal dose for each patient that maximize (2), then we use grid search to find the smallest θ
achieving the constraint on toxicity. Specifically the algorithm is as follows:
1. Set a grid 0 = θ1 < θ2 < ... < θK
2. For each m = 1, ...,K:
(a) set θ = θm
(b) For each subject i = 1, ..., n with covariate xi:
calculate dopti = argmax(δE(xi, d)− θδT (xi, d)), estimate P(E = 1|dopti , xi) and P(T = 1|dopti , xi)
3. Select the smallest θ̂ such that Ex[P(T = 1|dopti (θ), xi)] ≤ τ . Then dopti (θ̂) is the estimated optimal
dose for patient i.
For binary outcomes under the logistic link function, both δE(x, d) and δT (x, d) are functions involv-
ing the intercept, main effect of x, as well as dose related covariates d and dx. and Estimation of dopt
at given θ for each subject is solved by one-dimensional optimization using optimize() in R, which
uses a combination of golden section search and successive parabolic interpolation. Because of the non-
decreasing dose-efficacy and dose-toxicity relationship, a larger θ will recommend a smaller dopt, and the
corresponding population average efficacy and toxicity will be smaller. So the smallest θ achieving the
constraint on average toxicity will achieve the largest average efficacy. The range and size of the grid can
be pre-specified and should include a range of feasible values. In our simulation and data example, we
used a range of 0.01 to 4, in steps of 0.001. We note that for the determination of dopti , we consider the
subject level E − T trade-off, whilewhere as for the determination of θ, we look at the population level
E − T trade-off.
2.2 Multiple Outcome Setting
In some applications there are multiple toxicity outcomes which must be considered and balanced against
efficacy when selecting treatment dose. Without loss of generality, we consider two different toxicity
outcomes T1, T2 and the goal is to
maxF EF (E) , subject to EF (T1) ≤ τ1,EF (T2) ≤ τ2 (6)
where τ1, τ2 are the pre-specified maximal tolerance levels of average toxicity for each toxicity outcome.
Define δE(xi, di) =P(E = 1|di, xi)−P(E = 1|di = −1, x), δT1(xi, di) =P(T1 = 1|di, xi)−P(T1 =
1|di = −1, xi), δT2(xi, di) =P(T2 = 1|di, xi)−P(T2 = 1|di = −1, xi). Then equation (6) is equivalent
to
maxF Ex[δE{xi,F(xi)} − θ1δT1{xi,F(xi)} − θ2δT2{xi,F(xi)}], (7)
where θ1 > 0, θ2 > 0 are chosen such that Ex[δT1{xi,F(xi)}] ≤ τ1 − Ex[P(T1 = 1|di = −1, xi)], and
Ex[δT2{xi,F(xi)}] ≤ τ2 − Ex[P(T2 = 1|di = −1, xi)].
We specify parametric logistic models forE, T1, T2 as functions of biomarkers, dose, and dose-biomarker
interactions. Denote the parameter estimates from those logistic models as β̂E , β̂T1 , β̂T2 . We propose a ran-
dom walk and Metropolis algorithm to select θ1, θ2 to achieve the constraints on toxicity. The algorithm is
c© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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as follows:
1. Set a chain length, B, fix σ2 > 0 and initialize θ0 = (θ01, θ
0
2) to a starting value that makes Ex[P(T1 =
1|dopti (θ0), xi)] ≤ τ1,Ex[P(T2 = 1|dopti (θ0), xi)] ≤ τ2.
2. For b = 0, ..., B:
(a) Generate θ̃b+1 ∼ N(θb, σ2I) and θ̃b+1 > 0
(b) For each subject i = 1, ..., n with covariate xi:
compute dopti = argmax{δE(xi, d)− θ̃b+11 δT1(xi, d)− θ̃b+12 δT2(xi, d)}, estimate P(E = 1|dopti (θ̃b+1), xi),
P(T1 = 1|dopti (θ̃b+1), xi), and P(T2 = 1|dopti (θ̃b+1), xi)
(c) Compute q = min[1,Ex{P(E = 1|dopti (θ̃b+1), xi)}/Ex{Pr(E = 1|dopti (θb), xi)}]
(d) Generate U ∼ U(0, 1);
if Ex[P(T1 = 1|dopti (θ̃b+1), xi)] ≤ τ1,Ex[P(T2 = 1|dopti (θ̃b+1), xi)] ≤ τ2, and U ≤ q, set θb+1 = θ̃b+1;
otherwise, set θb+1 = θb
3. After generating a chain (θ0, ..., θB), we select the θk that leads to the largest value of Ex[P(E =
1|dopti (θk), xi)] as the optimal solution, and the dopti (θk) is the optimal dose for patient i.
In stage 2(b) in the above algorithmSimilarly, dopt at given θ for each subject is solved by one-
dimensional optimization using optimize() in R. Choose The variance of the proposal distribution
σ2 in stage 2(a) is chosen to make the acceptance proportion between 0.25 and 0.5. When there are mul-
tiple constraints we found that the random walk and Metropolis algorithm is more efficient than using a
finite grid search over the multiple dimensions of θ. In our experience, as long as the chain is long enough,
the maxima of the population average efficacy will be achieved. This can be checked by running the algo-
rithm in parallel for different initial choices of θ0. It is noted that there is no guarantee that both toxicity
constraints will be met at the boundary.
3 Simulation Studies
In this section, we performed numerical studies to investigate the performance of the proposed method
under different settings. All outcomes in this paper are binary, We simulated five i.i.d covariates, x1, ..., x5
from a standard normal distribution, d from Uniform(-1,1), and then generated N=200 binary outcomes E
and T from the regression models
logit(P(E = 1)) = β0,E +WEβE ,
logit(P(T = 1)) = β0,T +WTβT ,
where WE = WT = (x, d, dx). For A range of scenarios forwith β were considered, but we first describe
scenario 0, as given in Table 1. For scenario 0given in Table 1, we consider (β0,E , βE) =(0, 1, 0, 0,
0, 0, 1, .4, .4, .4, -.8, 0), and (β0,T , βT ) =(-1.386, -1, 0, 0, 0, 0, 1, -.4, -.4, -.4, .8, 0). In generating
x’s, we also applied the constraints that x must satisfy 1 + 0.4x1 + 0.4x2 + 0.4x3 − 0.8x4 > 0 and
1 − 0.4x1 − 0.4x2 − 0.4x3 + 0.8x4 > 0 to reflect the non-decreasing dose-efficacy and dose-toxicity
curves for all subjects. This excludes up to 35% of the originally simulated observations.
To illustrate the utility approach to dose selection, we plotted individual level E-T trade-off for three
different subjects in Fig.1 and population level E-T trade-off in Fig.2. Different dose-efficacy and dose-
toxicity curves among subjects result in selection of different optimal dose values across θ.
ForIn variable selection, we forced the main effect for dose to be selected by removing its associated
parameter from the penalty term and only consider the selection of covariates and dose*covariate interac-
tions. The methods we compared are forward selection (FS), regular LASSO, cLASSO and fixed dosing
(FD) in which dose only logistic models were fit. FS was implemented by step() in R using AIC as
criteria. Regular LASSO was implemented by glmnet() in R with 10-fold CV.
The boxplots in Fig.3 shows the average efficacy from the above methods with the same toxicity con-
straint, from which we see thatand cLASSO has higher average efficacy compared to the other methodswith
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others, especially fixed-dose. We also calculate the theoretical improvement from using the true models
which would only be known in a simulation study settingknown only in simulation. The improvement, de-
fined as proportion of possible gain compared to the gain from FD to theory, {EF (E)−EFFD (E)}/{EFTheory (E)−
EFFD (E)}, for FS, regular LASSO, and cLASSO is 0.513, 0.518, 0.589, respectively. cLASSO has higher
efficacy than LASSO for 69.0% of the simulated datasets.
We also considered a null case in whichwhen there are no covariates orand dose*covariates interac-
tions,so thatin other words, the dose effects are the same across all subjects. The average efficacy with
toxicity constrained at 0.2 for theory, FS, regular LASSO, cLASSO and FD are 0.503, 0.470, 0.490, 0.491,
0.499, respectively. With no effect of covariates, the dose-only model (FD) is as good as the theory, and the
models with covariates included have slightly worse performance than the dose-only model. ABut among
the modeling approaches, cLASSO has better performance than FSthe best performance.
A few other scenarios were considered: In scenario 1 there are only main effects of covariate and no
dose-covariate interactions, and the main effects of the same x are in opposite directions in efficacy and
toxicity models. In scenario 2, the dose-covariate interaction effects are the same in efficacy and toxicity
models, but the main effects of covariates are different. In scenario 3 and 4, there are 15 and 45 additional
noise covariates are added to increase p from 5 to 20 and 50, to examine the performance with high
dimensional data. In scenario 5 and 6, with the same coefficients as in scenario 0 and 3, the sample size
increased to 400. In practice, the covariates may be highly correlated resulting in multicollinearity. In
scenario 7, x’s are not independent and correlation among x1, x2, x3 are 0.6. We also considered several
situations in which the logistic regression model with linear effects is mis-specified. In scenario 8, the true
effect of covariate x4 is stepwise at 0, i.e., the effect only exits for x4 > 0. But when fitting models, it
is mis-specified as linear. In scenario 9, the true models have exp(x4) as the covariate, but in the fitted
models x4 is used, which is mis-specified. In scenario 10, an interaction of x2 and x3 is included as main
effect in both true models for efficacy and toxicity, but in the fitted models this interaction is not included.
Table 1 showed the simulation results with the above setting. We also considered another setting with
more covariate main effects and fewer dose-covariate interactions, and with the non-decreasing constraints,
12% of the simulated observations were excluded. In scenario 1 and 2, when the dose related coefficients
for efficacy and toxicity models are the same or 0, the main effects of covariates still played a role in
the optimal dose finding with the logistic link, and cLASSO still has better performance than the other
methods. In scenario 3 and 4, with the increased number of noise covariates, the magnitude of improvement
decreased, but the cLASSO still performs better than the other methods. In scenario 5 and 6, with the larger
sample sizes, the magnitude of improvement increased, and cLASSO outperforms the other methods.
In scenario 7, with correlated covariates where the performance of LASSO is known to be suboptimal,
cLASSO still performs better than LASSO and FS. In scenario 8, 9, and 10, when the logistic regression
model with linear effects is mis-specified, all the methods have smaller magnitude of improvement, but
cLASSO still performs better than LASSO and FS, showing the robustness of cLASSO.
In Table A1 in the Supplementary materials we present the results from simulations that considered
two toxicity outcomes, T1 and T2. The scenarios were constructed using a subset of the previous efficacy
and toxicity models as in Table 1 with toxicity outcome T2 added and constrained at 0.23. The situations
considered included a variety of biomarker main effects, dose-biomarker interactions, correlations between
the biomarkers and additional noise biomarkers. The results in Table A1 provide similar conclusions
regarding the relative merit of cLASSO compared to the other methods as in the single toxicity outcome
case.
4 Application
In this section, we applied the proposed method to the real data collected from a group of patients with
non-small cell lung cancer who received radiation treatment after surgery. Patients treated with stereotactic
body radiation therapy or with follow-up less than one year were excluded from the analysis, leaving 105
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patients in the dataset to be analyzedanalysis. Of the 105 patients, 46 had no local, regional or distant
progression in two years. The toxicity is measured by the level of adverse events from grade 1 to 5,
and t Two toxicity outcomes were considered: grade 3+ heart toxicity and grade 3+ lung toxicity. In
total, 8 patients had grade 3+severe heart toxicity, and 11 patients had grade 3+severe lung toxicity that
required hospitalizationneed medical treatment. The clinical features we consider for possible inclusion
in models includeare interested in are sex, age, current smoker, Karnofsky Performance Status (KPS),
concurrent chemotherapy, simple stage, T-stage, N-stage of the cancer, as shown in Table.2. We also
include pre-treatment cytokines level such as interferon γ (IFN-γ), interleukin-1 β (IL-1β), interleukin-2
(IL-2), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) as prognostic factors. Patients in this study
received different doses ranging from 45 Gy to 96 Gy, partially due to the preference of different clinicians
as well as the stage of the disease, location of the tumor and the patients performance status. The dose
to the tumor site (efficacy dose) is different from the dose received bys to the lung and heart (toxicity
doses), but we assume the ratio of them is fixed for each patient. When the optimal efficacy dose is chosen
withinbetween the observed dose range (45.66 - 96.08 Gy), it is multiplied by this known fixed (for each
patient)the ratio to obtain the lung and heart dose corresponding to the selected tumor doseoptimal toxicity
dose. There are 14 patients with no cytokine data collected, and multiple imputation with all the covariates
and outcomes included is applied to fill in the missing values.
For the given set of doses in the study, the average probability of no progression in two years (efficacy)
is 0.438, the average probability of heart toxicity is 0.076, the average probability of lung toxicity is 0.105,
and average tumor dose across patients is 71.20. The goal of this analysis is to estimate an optimal dosing
rule that maximize the probability of no progression in 2 years, with heart and lung toxicity level no
greater than observed overall toxicity for this population of patientsunder the same tolerance level. The
efficacy model for the probability of no progression in two years including as covariates the 8 clinical
features with their interactions with tumor dose as well as tumor dose has in total 17 possible covariates.
The heart toxicity model is built similarly, and the lung toxicity model also includes the 5 most important
pre-cytokines and their interaction with lung dose. Table 3 showed the covariates selection by cLASSO in
each model. The random walk method of selecting θ ran for 50001000 iterations to ensure convergence.
With the models built by cLASSO, using the selected optimal dose for each patient gave an expected
efficacy of 0.485, an expected heart toxicity at 0.0770.078, an expected lung toxicity at 0.108, and the
average tumor dose across patients was 80.2180.16 Gy. With similar expected lung toxicity and heart
toxicity rates, the average efficacy increased by 0.047 from 0.438 to 0.485, by 0.047.
5 Discussion
In this paper, we propose an optimal individualized dose finding rule by maximizing utility functions for
individual patients. This approach maximizes overall efficacy at a prespecified constraint on overall toxi-
city. We model the binary efficacy and toxicity outcomes using logistic regression with dose, biomarkers
and dose-biomarker interactions. To incorporate the larger number of biomarkers and their interaction
with doses, we employed the LASSO with linear constraints on the dose related coefficients to constrain
the dose effect to be non-negative. Simulation studies show that this approach can improve efficacy with-
out increasing toxicity relative to fixed dosing. Constraining each patient’s estimated dose-efficacy and
dose-toxicity curves to be non-decreasing improved performance relative to standard LASSO. This utility
method wascan be extended to multiple toxicities.
To force the dose-toxicity or dose-efficacy curve to be non-decreasing with dose, the constraints for
linear combination of dose related coefficients only ensure that the patients in the current data satisfy
this monotonicity criteria, but monotonicty is not guaranteed for all future patients whose x is not in
the observed data. An alternative approach that would ensure monotonicity with respect to dose for all
patients would be to force all relevant dose and dose-covariate coefficients to be non-negative. But with
the dose-biomarker interactions, it is unnecessaryinappropriate to force all the dose related coefficients
c© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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to be non-negative, because some of them could be negative but the linear combination of them is non-
negative for a selected range of dose and covariate values. Thus, simply constraining all the dose related
coefficients to be non-negative is too conservative. It is noted that our method is not appropriate in cases
where the toxicity or efficacy endpoint may first increase and then decrease with increasing dose, but is
still applicable when there is an increasing effect followed by a plateau.
While we implemented a constrained version of LASSO, other penalized regression approaches such as
Elastic Net could also be considered (Zou and Hastie, 2005), or Bayesian methods using Bayesian LASSO
(Park and Casella, 2008), or other Bayesian variable selection methods such as ”spike-and-slab” (Kuo and
Mallick, 1998).
Our method constrains the population averaged toxicity level to be below a given tolerance level. This
does not explicitly put any upper bound on the expected toxicity probability for an individual patient. Our
method could be modified by including an upper bound on the probability of toxicity for each patient. An
indirect way of achieving this would be to use a non-linear function of the probability of toxicity, rather
than just the toxicity rate in equation (1). Thus, in addition to constraints on average toxicity, we also
consider adding constraints to individual toxicity, i.e., adding large penalty for extremely high toxicity,
which will make the utility function more complex. An indirect way of achieving this would be to use a
non-linear function of the probability of toxicity, rather than just the toxicity rate in equation (1).
In this paper we have considered binary outcomes and logistic models that included main effect and
dose-biomarker interactions. The method could be generalized to other type of outcomes, such as censored
survival times for the efficacy outcome. An ordinal outcome for toxicity could also be accommodated by
requiring a different tolerance threshold for each level of toxicity. More flexible forms for the effect of dose
and biomarkers could also be considered (e.g., regression splines), and provided the dose monotonicity
constraint can be algebraically formulated, the cLASSO would still be applicable.
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Figure 1 Top: Individual level E-T plot with choice of dose with theoretical βE , βT for three subjects. The utility curve uses θ = 1. Bottom:
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Figure 2 Left: Population level E-T plot with choice of θ with theoretical βE , βT , Right: Population
level E-T trade-off at different toxicity tolerance levels.
Figure 3 Simulation results for scenario 0. Boxplot of average efficacy with same toxicity for 1000
simulation trials. The compared methods are theory with true coefficients; FS: Forward Selection; LASSO;
cLASSO: constrained LASSO; FD: Fixed Dosing. All methods are constrainted at P(T)=0.20. Means are
0.599, 0.528, 0.528, 0.539, 0.452, respectively.
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Table 1: Simulation results. Summary of average Efficacy improvement compared with fixed dose with P(Toxicity) constrained to be ≤ 0.2. ResultsT
constraint at 0.2 from 1000 simulated trials. Each scenario true logistic models for E and T include main effect for the biomarkers, dose and biomarker-
dose interactions, with coefficients as shown below.
Scenarios Efficacy and Toxicity model coefficients FS LASSO cLASSO Possible cLASSO >Biomarker Dose Interactions Improvement LASSO
0 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.513 0.518 0.589 0.147 69.0%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
1 E 1 0 0 0 0 1 0 0 0 0 0 0.393 0.659 0.694 0.052 53.3%T -1 0 0 0 0 1 0 0 0 0 0
2 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.344 0.340 0.375 0.070 56.7%T -1 0 0 0 0 1 .4 .4 .4 -.8 0
3 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.216 0.332 0.354 0.146 60.4%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
4 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 NA 0.246 0.272 0.146 60.0%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
5 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.692 0.691 0.762 0.148 71.7%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
6 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.433 0.431 0.461 0.148 66.3%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
7 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.561 0.561 0.628 0.147 66.2%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
8 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.378 0.399 0.450 0.200 58.2%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
9 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.360 0.402 0.481 0.206 64.6%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
10 E 1 0 0 0 0 1 .4 .4 .4 -.8 0 0.455 0.466 0.551 0.146 69.3%T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
0?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.618 0.648 0.694 0.132 62.9%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
1?
E 1 .2 .3 .1 0 1 0 0 0 0 0 0.410 0.590 0.641 0.055 56.4%T -1 -.2 -.3 -.1 0 1 0 0 0 0 0
2?
















































Scenarios Efficacy and Toxicity model coefficients FS LASSO cLASSO Possible cLASSO >Biomarker Dose Interactions Improvement LASSO
3?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.280 0.429 0.460 0.131 62.1%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
4?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 NA 0.307 0.342 0.133 61.7%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
5?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.788 0.802 0.833 0.134 64.0%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
6?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.512 0.613 0.640 0.133 62.0%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
7?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.671 0.716 0.756 0.134 65.0%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
8?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.391 0.435 0.457 0.153 54.8%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
9?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.317 0.372 0.435 0.081 65.6%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
10?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.519 0.559 0.624 0.132 68.4%T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
a. The intercept for Efficacy models is 0, for Toxicity models is -1.386.
b. Possible Improvement=EFTheory (E)− EFFD (E), the percentage of improvement={EF (E)− EFFD (E)}/{EFTheory (E)− EFFD (E)}.
c. Scenarios 3, 6, 3?, 6? have 15 noise covariates with coefficients 0 added; scenarios 4, 4? have 45 noise covariates with coefficients 0 added.
d. Scenarios 5, 6, 5?, 6? have doubled sample size of 400.
e. Scenario 7, 7? have cor(x1, x2, x3) = 0.6.
f. Scenarios 8, 9, 10, 8?, 9?, 10? have mis-specified models.
In scenario 8, 8?, the true effect of covariate x4 is stepwise at 0, e.g.,logit(P(E = 1)) = x1 + d+ (0.4x1 + 0.4x2 + 0.4x3 − 0.8I(x4 > 0))d.
In scenario 9, 9?, the true models have exp(x4) as the covariate,e.g.,logit(P(E = 1)) = x1 + d+ (0.4x1 + 0.4x2 + 0.4x3 − 0.8exp(x4))d.
In scenario 10, 10?, an interaction of x2 and x3 is included as main effect in both true models for efficacy and toxicity,
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Table 2 Descriptive statistics of patients (n=105)
Variable Mean Range
Age (Years) 65.43 39.60 - 85.20
KPS 85.52 60 -100
IFN-γ 113.31 0.52 - 6547.50
IL-1β 10.26 0.04 - 92.61
IL-2 23.50 0.04 - 312.22
IL-6 41.93 0.07 - 730.84
TNF-α 18.48 0.54 - 149.37
Tumor dose (Gy) 71.20 45.66 - 96.08
Lung dose (Gy) 14.47 3.17 - 26.11





Never or former 58
chemotherapy Yes 85
No 15
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Table 3 Variable selections in each model
Method cLASSO
Model Efficacy Heart toxicity Lung toxicity
Main effect




























Estimated outcomes if these patients were treated at optimal doses 0.485 0.0770.078 0.108
− represents a covariate which is not considered for inclusion in the model.
? represents a covariate selected by cLASSO for the corresponding model.
Empty cell represent covariates considered for inclusion but not selected by cLASSO.
Appendix A: Proof
The minimizer to problem (4) always satisfies β+j β
−
j = 0 for j = 1, ..., 2p+ 1.
P r o o f. Proof by contradiction: Consider the minimizer of (4) β = β+− β−. Without loss of general-
ity, assume we have β+1 > 0, β
−
1 > 0. Consider another representation of the same β = β̃+ − β̃−.
β̃+1 = β
+







j for j = 2, ..., 2p+ 1








1 − β̃−1 =
β+1 − β−1 .
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> −∑ni=1
{







This contradicts with the assumption that (β+, β−) is the minimizer of (4).
Appendix B: Additional simulation results
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Table A1: Simulation results for two toxicities. Summary of average Efficacy improvement compared with fixed dose with P(Toxicity1) constrained to
be ≤ 0.2 and P(Toxicity2) constrained to be ≤ 0.23. Results from 1000 simulated trials. Each scenario true logistic models for E, T1 and T2 include
main effect for the biomarkers, dose and biomarker-dose interactions, with coefficients as shown below.
Scenarios Efficacy and Toxicity model coefficients FS LASSO cLASSO Possible cLASSO >Biomarker Dose Interactions Improvement LASSO
A0
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.581 0.549 0.606 0.121 66.3%T1 -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A1 E 1 0 0 0 0 1 0 0 0 0 0 0.682 0.781 0.800 0.036 50.2%T1 -1 0 0 0 0 1 0 0 0 0 0
T2 -1 0 0 0 0 1 0 0 0 0 0
A2
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.639 0.627 0.695 0.114 67.2%T1 -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A3
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.454 0.471 0.510 0.121 59.3%T1 -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A0? E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.659 0.661 0.705 0.111 62.3%T1 -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A1? E 1 .2 .3 .1 0 1 0 0 0 0 0 0.575 0.677 0.700 0.039 50.9%T1 -1 -.2 -.3 -.1 0 1 0 0 0 0 0
T2 -1 0 0 0 0 1 0 0 0 0 0
A2? E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.702 0.667 0.731 0.125 55.1%T1 -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A3? E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0 0.622 0.593 0.658 0.115 60.3 %T1 -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
a. The intercept for Efficacy models is 0, for Toxicity1 models is -1.386, for Toxicity2 models is -1.2
b. Possible Improvement=EFTheory (E)− EFFD (E), the percentage of improvement={EF (E)− EFFD (E)}/{EFTheory (E)− EFFD (E)}.
c. The random walk method of selecting θ was run for 1000 iterations.
d. Scenario A2, A2? have cor(x1, x2, x3) = 0.6.
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Figure 1 Top: Individual level E-T plot with choice of dose with theoretical βE , βT for three subjects. The 
utility curve uses θ = 1. Bottom: Individual level optimal dose as a function of θ for the same three subjects. 
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Figure 2 Left: Population level E-T plot with choice of θ with theoretical βE , βT , Right: Population level E-T 
trade-off at different toxicity tolerance levels. 
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Figure 3 Simulation results for scenario 0. Boxplot of average efficacy with same toxicity for 1000 simulation 
trials. The compared methods are theory with true coefficients; FS: Forward Selection; LASSO; cLASSO: 
constrained LASSO; FD: Fixed Dosing. All methods are constrainted at P(T)=0.20. Means are 0.599, 0.528, 
0.528, 0.539, 0.452, respectively. 
338x190mm (300 x 300 DPI) 
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